KDM1/LSD1 Degrader

LD-110 triTFA is a PROTAC degrader targeting LSD1 with a DC₅₀ of 0.44-1.24 μM. LD-110 triTFA acts through the CRBN E3 ubiquitin ligase and the ubiquitin-proteasome system, leading to H3K4me2 accumulation. LD-110 triTFA induces apoptosis and inhibits the growth and survival of multiple esophageal squamous cell carcinoma (ESCC) cell lines. LD-110 triTFA inhibits tumor growth in the KYSE-150 xenograft model. LD-110 triTFA can be used in research related to esophageal squamous cell carcinoma.

LD-110 trihydrochloride is a PROTAC degrader targeting LSD1 with a DC₅₀ of 0.44-1.24 μM. LD-110 trihydrochloride acts through the CRBN E3 ubiquitin ligase and the ubiquitin-proteasome system, leading to H3K4me2 accumulation. LD-110 trihydrochloride induces apoptosis and inhibits the growth and survival of multiple esophageal squamous cell carcinoma (ESCC) cell lines. LD-110 trihydrochloride inhibits tumor growth in the KYSE-150 xenograft model. LD-110 trihydrochloride can be used in research related to esophageal squamous cell carcinoma.

LD-110 is a PROTAC degrader targeting LSD1 with a DC₅₀ of 0.44-1.24 μM. LD-110 acts through the CRBN E3 ubiquitin ligase and the ubiquitin-proteasome system, leading to H3K4me2 accumulation. LD-110 induces apoptosis and inhibits the growth and survival of multiple esophageal squamous cell carcinoma (ESCC) cell lines. LD-110 inhibits tumor growth in the KYSE-150 xenograft model. LD-110 can be used in research related to esophageal squamous cell carcinoma.